Skip to content
DataLookout
Menu

NCT06224257

Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia

StatusCompleted
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 23 words
    • Trial completed
    • Site details revised at 3 of 3 sites
  2. Minor Primary completion date: Jun 30, 2025 to Oct 31, 2025
    • Study completion date: Oct 31, 2025 to Jan 31, 2026
    v2
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Proportion of patients with hematologic remission
Timeframe: 8-12 weeks

Secondary (1)

Incidence of the adverse event

Arms and interventions

LinperlisibExperimental

Linperlisib was administered at 80 mg every day, orally in a 28-day cycle until disease progression or intolerable toxicity occurred.

Drugs: Linperlisib

Sites

3 sites in 1 country